Page 1

00 . THERA technologies Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024 • Q1 2024 consolidated revenue of $ 16.2 million • Report marks third consecutive quarter of near - flat - to - positive Adjusted EBITDA • FY2024 revenue guidance confirmed between $ 87 and $ 90 million and an Adjusted EBITDA in the range of $ 13-15 million • Acceleration of Phase 1 trial of sudocetaxel zendusortide in advanced ovarian cancer with enrollment of next cohort of patients underway at higher dose level -- MONTREAL , April 10 , 2024 Theratechnologies Inc. ( " Theratechnologies " or the " Company " ) ( TSX : TH ) ( NASDAQ : THTX ) , a biopharmaceutical company focused on the development and commercialization of innovative therapies , today reported business highlights and financial results for the first quarter of fiscal year 2024 ended February 29 , 2024 ( Q1 2024 ) . All figures are in US dollars unless otherwise stated . " I am pleased to wrap up the quarter by reaffirming our full year 2024 guidance of revenues between $ 87 and $ 90 million and an Adjusted EBITDA in the range of $ 13-15 million . Our new cost structure together with our strategic focus on commercial capabilities puts Theratechnologies on the brink of producing stronger cash flow and value for shareholders , ” said Paul Lévesque , President and Chief Executive Officer at Theratechnologies . “ EGRIFTA SV® continues to be our engine of growth and according to key performance metrics such as enrollments and unique patients , we are on track to achieve and even surpass our long - term objectives . As anticipated during our recent fourth quarter call , we are experiencing some variability in revenue growth reporting based on the buildup and subsequent drawdown of inventories in the early part of fiscal 2023. Despite lower revenues this quarter , we expect a reverse trend in the second quarter and an evening out of revenues in the second half of 2024. We continue to demonstrate strength on the bottom line , with an improved net loss of $ 4.4 million versus a net loss of $ 10.4 million in Q1 2023. This quarter also marks our third consecutive quarter of near - flat - to - positive Adjusted EBITDA , up more than $ 3.6 million² from Q1 2023. " Lévesque added , " Following our recent Type A meeting with the FDA on the sBLA for tesamorelin F8 , we remain on track to resubmit our file and receive a decision from the FDA on this new product formulation before the end of 2024. With M & A more important than ever to the evolution of portfolio and our overall growth strategy , I am confident that our positive trajectory of Adjusted EBITDA will facilitate the acquisition of new assets that should contribute to value creation for our business . We continue to prioritize our Phase 1 clinical trial studying sudocetaxel zendusortide in advanced ovarian cancer and welcome its acceleration with the recent milestone of the enrollment of the next cohort of patients at the higher dose level . Now that we have significantly advanced our oncology program with important evidence on multiple PDCs with different payloads , coupled with the more than 40 patients already treated with sudocetaxel zendusortide , we believe we are in a position of strength to continue engaging with a partner for additional developmental steps . " First - Quarter 2024 Revenues ( in thousands of U.S. dollars ) Three Months Ended Change February 29 , 2024 February 28 , 2023 EGRIFTA SVⓇ net sales Trogarzo net sales 9,586 6,661 12,711 ( 24.6 % ) Revenue 16,247 7,197 19,908 ( 7.4 % ) ( 18.4 % ) Recent Highlights : Sudocetaxel Zendusortide ( TH1902 ) and SORT1 + Technology ™ On February 15 , 2024 , the Company announced the completion of enrollment of the first six participants in Part 3 of its Phase 1 clinical trial of sudocetaxel zendusortide in patients with advanced ovarian cancer , and on March 21 , 2024 , we announced that we were moving to the next dose level in Part 3 of its Phase 1 clinical trial of sudocetaxel zendusortide in patients with advanced ovarian cancer . The study's Medical Review Committee ( MRC ) has deemed the dose level in the first cohort of patients safe and has approved initiation of the next cohort with an increased dose , in accordance with the updated dose optimization protocol . Study centers are now actively recruiting patients for the second cohort , with one patient already enrolled and treated with the higher dose .